IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Bridges Investment Management Inc.

Bridges Investment Management Inc. lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,169 shares of the medical research company’s stock after selling 655 shares during the quarter. Bridges Investment Management Inc.’s holdings in IQVIA were worth $2,173,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new position in IQVIA in the first quarter valued at $700,000. Empowered Funds LLC lifted its holdings in shares of IQVIA by 35.5% during the 1st quarter. Empowered Funds LLC now owns 2,512 shares of the medical research company’s stock worth $635,000 after acquiring an additional 658 shares during the period. Sei Investments Co. boosted its position in shares of IQVIA by 4.8% in the first quarter. Sei Investments Co. now owns 57,887 shares of the medical research company’s stock worth $14,638,000 after acquiring an additional 2,638 shares during the last quarter. NorthRock Partners LLC purchased a new stake in IQVIA in the first quarter valued at approximately $233,000. Finally, Meeder Advisory Services Inc. increased its position in IQVIA by 5.7% during the first quarter. Meeder Advisory Services Inc. now owns 3,148 shares of the medical research company’s stock worth $796,000 after purchasing an additional 169 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Performance

IQVIA stock opened at $219.23 on Friday. IQVIA Holdings Inc. has a 52 week low of $190.20 and a 52 week high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market cap of $39.79 billion, a P/E ratio of 28.77, a price-to-earnings-growth ratio of 2.26 and a beta of 1.51. The stock has a 50 day moving average of $231.00 and a 200-day moving average of $229.31.

Analysts Set New Price Targets

A number of equities analysts have weighed in on IQV shares. BTIG Research decreased their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and decreased their target price for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. TD Cowen cut their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Barclays decreased their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $259.13.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.